Abstract
Approximately 50% of patients (pts) with metastatic melanoma have BRAF V600 mutations, which promote melanoma progression through constitutive activation of the MAPK pathway. Current treatment recommendations for metastatic or unresectable BRAF V600-mutant melanoma include BRAF inhibitors (BRAFi) + MEK inhibitors (MEKi) (eg, enco + bini) and immune checkpoint inhibitors (CPIs; eg, pembro). BRAFi and MEKi may increase the sensitivity of BRAF V600-mutant tumors to CPIs. STARBOARD aims to compare the efficacy, safety, and tolerability of first-line enco + bini + pembro vs pembro alone for the treatment of metastatic or unresectable locally advanced BRAF V600-mutant melanoma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
